Tonix Pharmaceuticals Holding Corp. SEC filings TNXP
Tonix Pharmaceuticals Holding Corp. has 1,000 filings in SEC EDGAR's recent list, going back to May 2, 2017. Its latest annual report, Form ARS, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 4, 2025 | — |
| CORRESP | Letter to the SEC | Sep 3, 2025 | — |
| CORRESP | Letter to the SEC | Sep 3, 2025 | — |
| CORRESP | Letter to the SEC | Aug 29, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2025 | — |
| EFFECT | Filing | Sep 30, 2024 | — |
| CORRESP | Letter to the SEC | Sep 26, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| NT 10-Q | Notice under rule 12b25 of inability to timely file | Aug 15, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Aug 26, 2022 | — |
| CORRESP | Letter to the SEC | Aug 24, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2021 | — |
| CORRESP | Letter to the SEC | Jun 25, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2021 | — |
| EFFECT | Filing | May 5, 2021 | — |
| CORRESP | Letter to the SEC | May 4, 2021 | — |
| CORRESP | Letter to the SEC | Apr 23, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2021 | — |
| EFFECT | Filing | Jan 4, 2021 | — |
| CORRESP | Letter to the SEC | Dec 30, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2020 | — |
| EFFECT | Filing | Apr 17, 2020 | — |
| CORRESP | Letter to the SEC | Apr 15, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 18, 2020 | — |
| EFFECT | Filing | Feb 6, 2020 | — |
| CORRESP | Letter to the SEC | Feb 6, 2020 | — |
| CORRESP | Letter to the SEC | Feb 6, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 4, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 24, 2020 | — |
| EFFECT | Filing | Nov 14, 2019 | — |
| CORRESP | Letter to the SEC | Nov 14, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2019 | — |
| EFFECT | Filing | Sep 11, 2019 | — |
| CORRESP | Letter to the SEC | Sep 9, 2019 | — |
| CORRESP | Letter to the SEC | Sep 6, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2019 | — |
| POS EX | Post-effective amendment | Jul 16, 2019 | — |
| EFFECT | Filing | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 11, 2019 | — |
| CORRESP | Letter to the SEC | Jul 9, 2019 | — |
| CORRESP | Letter to the SEC | Jul 9, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 24, 2019 | — |
| EFFECT | Filing | Dec 7, 2018 | — |
| CORRESP | Letter to the SEC | Dec 4, 2018 | — |
| CORRESP | Letter to the SEC | Dec 4, 2018 | — |
| EFFECT | Filing | Nov 5, 2018 | — |
| EFFECT | Filing | May 16, 2018 | — |
| CORRESP | Letter to the SEC | May 14, 2018 | — |
| UPLOAD | Letter from the SEC | May 9, 2018 | — |
| EFFECT | Filing | Oct 12, 2017 | — |
| D | Filing | Oct 10, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 10, 2017 | — |
| CORRESP | Letter to the SEC | Oct 10, 2017 | — |
| RW | Filing | Sep 15, 2017 | — |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1430306
- Former names
- TAMANDARE EXPLORATIONS INC. (until Oct 17, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.